Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

被引:98
作者
Yao, Xingjun [1 ]
Zhao, Gang [1 ]
Yang, Hongfa [1 ]
Hong, Xinyu [1 ]
Bie, Li [1 ]
Liu, Guojin [1 ]
机构
[1] Jilin Univ, Affiliated Hosp 1, Dept Surg, Changchun 130021, Peoples R China
关键词
HMGB1; Progression; Prognosis; Colorectal cancer; GLYCATION END-PRODUCTS; PROTEIN HMGB1; CYCLOOXYGENASE-2; EXPRESSION; CANCER; AMPHOTERIN; RECEPTOR; METASTASIS; LIGAND; CELLS; B1;
D O I
10.1007/s00432-009-0706-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-mobility group box 1 (HMGB1) has been implicated in a variety of biologically important processes, including transcription, DNA repair, V(D)J recombination, differentiation, development, and extracellular signaling. The increased expression of HMGB1 has been described in colorectal cancer (CRC). However, there is no report about the correlation of HMGB1 with clinicopathologic features, including the survival of patients with CRC. In present study, we investigated HMGB1 expression and its prognostic significance in CRC by performing immunohistochemical analysis, using a total of 192 paraffin-embedded archival CRC samples. Moreover, disruption of endogenous HMGB1 protein through a siRNA knockdown technique was performed to investigate the possible role of HMGB1 in the process of tumor invasion and metastasis. Overexpression of HMGB1 was shown in 55.7% cases. Statistical analysis showed that HMGB1 expression was positively correlated with tumor invasion (P = 0.048), lymph node metastasis (P = 0.011), distant metastasis (P = 0.031), and Duke's stage (P = 0.029) of CRC patients. Patients with higher HMGB1 expression had shorter overall survival time, whereas patients with lower level of HMGB1 had better survival. Multivariate analysis suggested that HMGB1 expression might be an independent prognostic indicator for the survival of patients with CRC. Disruption of endogenous HMGB1 protein through a siRNA knockdown technique was shown to suppress substantially the invasion ability of SW620 cells. Our results suggest that HMGB1 protein is a valuable marker for progression of CRC patients. High HMGB1 expression is associated with poor overall survival in patients with CRC.
引用
收藏
页码:677 / 684
页数:8
相关论文
共 22 条
[1]  
Choi YR, 2003, CANCER RES, V63, P2188
[2]   Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer [J].
Chung, Hye Won ;
Lee, Sang-Guk ;
Kim, Heejung ;
Hong, Duck Jin ;
Chung, Jae Bock ;
Stroncek, David ;
Lim, Jong-Baeck .
JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
[3]   Dual roles for HMGB1: DNA binding and cytokine [J].
Czura, CJ ;
Wang, HC ;
Tracey, KJ .
JOURNAL OF ENDOTOXIN RESEARCH, 2001, 7 (04) :315-321
[4]   BIOLOGY OF HUMAN COLON-CANCER METASTASIS [J].
GUTMAN, M ;
FIDLER, IJ .
WORLD JOURNAL OF SURGERY, 1995, 19 (02) :226-234
[5]   Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways [J].
Huttunen, HJ ;
Fages, C ;
Rauvala, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (28) :19919-19924
[6]   Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development [J].
Ishiguro, H ;
Nakaigawa, N ;
Miyoshi, Y ;
Fujinami, K ;
Kubota, Y ;
Uemura, H .
PROSTATE, 2005, 64 (01) :92-100
[7]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[8]   Global gene expression profiles of human head and neck squamous carcinoma cell lines [J].
Jeon, GA ;
Lee, JS ;
Patel, V ;
Gutkind, JS ;
Thorgeirsson, SS ;
Kim, FC ;
Chu, IS ;
Amornphimoltham, P ;
Park, MH .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (02) :249-258
[9]   Differential effects between amphoterin and advanced glycation end products on colon cancer cells [J].
Kuniyasu, H ;
Chihara, Y ;
Kondo, H .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (06) :722-727
[10]  
Kuniyasu H, 2003, ONCOL REP, V10, P445